FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308449920> ?p ?o ?g. }

• W4308449920 abstract "Abstract Background Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatric AML patients show high expression of the CD123 antigen, and this finding provides the biological basis to target CD123 with the chimeric antigen receptor (CAR). However, CAR.CD123 therapy in AML is hampered by on-target off-tumour toxicity and a long “vein-to-vein” time. Methods We developed an off-the-shelf product based on allogeneic natural killer (NK) cells derived from the peripheral blood of healthy donors and engineered them to express a second-generation CAR targeting CD123 (CAR.CD123). Results CAR.CD123-NK cells showed significant anti-leukaemia activity not only in vitro against CD123 + AML cell lines and CD123 + primary blasts but also in two animal models of human AML-bearing immune-deficient mice. Data on anti-leukaemia activity were also corroborated by the quantification of inflammatory cytokines, namely granzyme B (Granz B), interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α), both in vitro and in the plasma of mice treated with CAR.CD123-NK cells. To evaluate and compare the on-target off-tumour effects of CAR.CD123-T and NK cells, we engrafted human haematopoietic cells (hHCs) in an immune-deficient mouse model. All mice infused with CAR.CD123-T cells died by Day 5, developing toxicity against primary human bone marrow (BM) cells with a decreased number of total hCD45 + cells and, in particular, of hCD34 + CD38 − stem cells. In contrast, treatment with CAR.CD123-NK cells was not associated with toxicity, and all mice were alive at the end of the experiments. Finally, in a mouse model engrafted with human endothelial tissues, we demonstrated that CAR.CD123-NK cells were characterized by negligible endothelial toxicity when compared to CAR.CD123-T cells. Conclusions Our data indicate the feasibility of an innovative off-the-shelf therapeutic strategy based on CAR.CD123-NK cells, characterized by remarkable efficacy and an improved safety profile compared to CAR.CD123-T cells. These findings open a novel intriguing scenario not only for the treatment of refractory/resistant AML patients but also to further investigate the use of CAR-NK cells in other cancers characterized by highly difficult targeting with the most conventional T effector cells." @default.
• W4308449920 created "2022-11-12" @default.
• W4308449920 creator A5002997724 @default.
• W4308449920 creator A5003461736 @default.
• W4308449920 creator A5003586249 @default.
• W4308449920 creator A5016280304 @default.
• W4308449920 creator A5017556252 @default.
• W4308449920 creator A5022712318 @default.
• W4308449920 creator A5023213723 @default.
• W4308449920 creator A5027991901 @default.
• W4308449920 creator A5028114727 @default.
• W4308449920 creator A5032335251 @default.
• W4308449920 creator A5032696007 @default.
• W4308449920 creator A5041331809 @default.
• W4308449920 creator A5046871252 @default.
• W4308449920 creator A5047993250 @default.
• W4308449920 creator A5051153810 @default.
• W4308449920 creator A5057510030 @default.
• W4308449920 creator A5058119554 @default.
• W4308449920 creator A5059073164 @default.
• W4308449920 creator A5063437973 @default.
• W4308449920 creator A5071908701 @default.
• W4308449920 creator A5072559544 @default.
• W4308449920 creator A5080470691 @default.
• W4308449920 creator A5085927346 @default.
• W4308449920 date "2022-11-05" @default.
• W4308449920 modified "2023-10-17" @default.
• W4308449920 title "Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia" @default.
• W4308449920 cites W1491394604 @default.
• W4308449920 cites W1967995010 @default.
• W4308449920 cites W1972178991 @default.
• W4308449920 cites W2013971016 @default.
• W4308449920 cites W2017960234 @default.
• W4308449920 cites W2078489918 @default.
• W4308449920 cites W2121578398 @default.
• W4308449920 cites W2137605834 @default.
• W4308449920 cites W2137906256 @default.
• W4308449920 cites W2143034151 @default.
• W4308449920 cites W2146300845 @default.
• W4308449920 cites W2152442991 @default.
• W4308449920 cites W2154888794 @default.
• W4308449920 cites W2158240777 @default.
• W4308449920 cites W2161096609 @default.
• W4308449920 cites W2200370351 @default.
• W4308449920 cites W2208401755 @default.
• W4308449920 cites W2427154682 @default.
• W4308449920 cites W2606654718 @default.
• W4308449920 cites W2615682320 @default.
• W4308449920 cites W2749319028 @default.
• W4308449920 cites W2765972717 @default.
• W4308449920 cites W2772126867 @default.
• W4308449920 cites W2787301955 @default.
• W4308449920 cites W2787621143 @default.
• W4308449920 cites W2811405063 @default.
• W4308449920 cites W2893443002 @default.
• W4308449920 cites W2903930842 @default.
• W4308449920 cites W2905654445 @default.
• W4308449920 cites W2919051790 @default.
• W4308449920 cites W2942184366 @default.
• W4308449920 cites W2949701341 @default.
• W4308449920 cites W2952168835 @default.
• W4308449920 cites W2968297637 @default.
• W4308449920 cites W2980712409 @default.
• W4308449920 cites W2981234956 @default.
• W4308449920 cites W2989972949 @default.
• W4308449920 cites W2990828932 @default.
• W4308449920 cites W3004611567 @default.
• W4308449920 cites W3006483160 @default.
• W4308449920 cites W3022991438 @default.
• W4308449920 cites W3034816469 @default.
• W4308449920 cites W3044350523 @default.
• W4308449920 cites W3115869600 @default.
• W4308449920 cites W3128962475 @default.
• W4308449920 cites W3130903278 @default.
• W4308449920 cites W3149275202 @default.
• W4308449920 cites W3157831753 @default.
• W4308449920 cites W3158070586 @default.
• W4308449920 cites W3159397045 @default.
• W4308449920 cites W3166061664 @default.
• W4308449920 cites W3182107682 @default.
• W4308449920 cites W3193696103 @default.
• W4308449920 cites W3204209398 @default.
• W4308449920 cites W3206024522 @default.
• W4308449920 cites W4226247176 @default.
• W4308449920 cites W2409501023 @default.
• W4308449920 cites W3094766109 @default.
• W4308449920 doi "https://doi.org/10.1186/s13045-022-01376-3" @default.
• W4308449920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36335396" @default.
• W4308449920 hasPublicationYear "2022" @default.
• W4308449920 type Work @default.
• W4308449920 citedByCount "17" @default.
• W4308449920 countsByYear W43084499202022 @default.
• W4308449920 countsByYear W43084499202023 @default.
• W4308449920 crossrefType "journal-article" @default.
• W4308449920 hasAuthorship W4308449920A5002997724 @default.
• W4308449920 hasAuthorship W4308449920A5003461736 @default.
• W4308449920 hasAuthorship W4308449920A5003586249 @default.
• W4308449920 hasAuthorship W4308449920A5016280304 @default.
• W4308449920 hasAuthorship W4308449920A5017556252 @default.
• W4308449920 hasAuthorship W4308449920A5022712318 @default.

• next